RT Journal Article
SR Electronic
T1 Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.25.21252477
DO 10.1101/2021.02.25.21252477
A1 Vivek Shinde
A1 Sutika Bhikha
A1 Zaheer Hoosain
A1 Moherndran Archary
A1 Qasim Bhorat
A1 Lee Fairlie
A1 Umesh Lalloo
A1 Mduduzi S. L. Masilela
A1 Dhayendre Moodley
A1 Sherika Hanley
A1 Leon Fouche
A1 Cheryl Louw
A1 Michele Tameris
A1 Nishanta Singh
A1 Ameena Goga
A1 Keertan Dheda
A1 Coert Grobbelaar
A1 Gertruida Kruger
A1 Nazira Carrim-Ganey
A1 Vicky Baillie
A1 Tulio de Oliveira
A1 Anthonet Lombard Koen
A1 Johan J. Lombaard
A1 Rosie Mngqibisa
A1 As’ad Ebrahim Bhorat
A1 Gabriella Benadé
A1 Natasha Lalloo
A1 Annah Pitsi
A1 Pieter-Louis Vollgraaff
A1 Angelique Luabeya
A1 Aliasgar Esmail
A1 Friedrich G. Petrick
A1 Aylin Oommen Jose
A1 Sharne Foulkes
A1 Khatija Ahmed
A1 Asha Thombrayil
A1 Lou Fries
A1 Shane Cloney-Clark
A1 Mingzhu Zhu
A1 Chijioke Bennett
A1 Gary Albert
A1 Emmanuel Faust
A1 Joyce S. Plested
A1 Andreana Robertson
A1 Susan Neal
A1 Iksung Cho
A1 Greg M. Glenn
A1 Filip Dubovsky
A1 Shabir A. Madhi
A1 for the 2019nCoV-501 Study Group
YR 2021
UL http://medrxiv.org/content/early/2021/03/03/2021.02.25.21252477.abstract
AB Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the Covid-19 pandemic. Evaluation of Covid-19 vaccine efficacy against SARS-CoV-2 variants is urgently needed to inform vaccine development and use.Methods In this phase 2a/b, multicenter, randomized, observer-blinded, placebo-controlled trial in South Africa, healthy human immunodeficiency virus (HIV)-negative adults (18 to 84 years) or medically stable people living with HIV (PLWH) (18 to 84 years) were randomized in a 1:1 ratio to receive two doses, administered 21 days apart, of either NVX-CoV2373 nanoparticle vaccine (5 µg recombinant spike protein with 50 µg Matrix-M1 adjuvant) or placebo. The primary endpoints were safety and vaccine efficacy ≥7 days following the second dose against laboratory-confirmed symptomatic Covid-19 in previously SARS-CoV-2 uninfected participants.Results A total of 4387 participants were randomized and dosed at least once, 2199 with NVX-CoV2373 and 2188 with placebo. Approximately 30% of participants were seropositive at baseline. Among 2684 baseline seronegative participants (94% HIV-negative; 6% PLWH), there were 15 and 29 predominantly mild to moderate Covid-19 cases in NVX-CoV2373 and placebo recipients, respectively; vaccine efficacy was 49.4% (95% confidence interval [CI]: 6.1 to 72.8). Efficacy in HIV-negative participants was 60.1% (95% CI: 19.9 to 80.1), and did not differ by baseline serostatus. Of the primary endpoint cases with available whole genome sequencing, 38 (92.7%) of 41 were the B.1.351 variant. Post-hoc vaccine efficacy against B.1.351 was 51.0% (95% CI: - 0.6 to 76.2) in HIV-negative participants. Among placebo recipients, the incidence of symptomatic Covid-19 was similar in baseline seronegative vs baseline seropositive participants during the first 2 months of follow-up (5.3% vs 5.2%). Preliminary local and systemic reactogenicity were primarily mild to moderate and transient, and higher with NVX-CoV2373; serious adverse events were rare in both groups.Conclusions The NVX-CoV2373 vaccine was efficacious in preventing Covid-19, which was predominantly mild to moderate and due to the B.1.351 variant, while evidence of prior infection with the presumptive original SARS-CoV-2 did not confer protection against probable B.1.351 disease. (Funded by Novavax, The Bill and Melinda Gates Foundation, and the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04533399)Competing Interest StatementDisclosure forms provided by the authors are available with the full text of this article at NEJM.org.Clinical TrialNCT04533399Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04533399?term=NVX-CoV2373+Covid-19+Vaccine&draw=2&rank=2 Funding StatementSupported by Novavax, Inc., The Bill and Melinda Gates Foundation, and the Coalition for Epidemic Preparedness Innovations.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the South African Health Products Regulatory Authority (SAHPRA; Ref 20200420) and Institutional Ethics Review Boards and registered in Clinicaltrials.gov (NCT04533399 and the Pan African Clinical trials Registry (PACTR202009726132275). Safety oversight, including for specific vaccination pause rules, was performed by an independent safety monitoring committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThese are interim data, and individual participants remain masked to individual vaccine assignment. Therefore, it would be inappropriate to share individual level results at this time. https://clinicaltrials.gov/ct2/show/NCT04533399?term=NVX-CoV2373+Covid-19+Vaccine&draw=2&rank=2 http://www.novavax.com